Search

MSK researchers have shown for the first time that the concentration of different types of immune cells in the blood changes in relation to the presence of different bacterial strains in the gut.

… Wednesday, November 25, 2020 Summary MSK researchers have uncovered an important finding about the relationship between the microbiota and the immune system, showing for the first time that the concentration of different types of immune cells in the blood changes in relation to the presence of different

Scott W. Lowe, PhD, Chair of the Cancer Biology and Genetics Program at the Sloan Kettering Institute (SKI), Howard Hughes Medical Institute Investigator, and Chair of the Geoffrey Beene Cancer Research Center, has been elected to the National Academy of Medicine (NAM), one of the highest honors bestowed upon scientists worldwide.

… Monday, October 21, 2019 Scott W. Lowe, PhD , Chair of the Cancer Biology and Genetics Program at the Sloan Kettering Institute (SKI), Howard Hughes Medical Institute Investigator, and Chair of the Geoffrey Beene Cancer Research Center, has been elected to the National Academy of Medicine (NAM) , one

Cell biologists are finding surprising overlaps between a particular form of programmed cell death and the process of wound detection.

… Wednesday, January 1, 2020 Cell biologist Philipp Niethammer left the camera running while he went to get a cup of coffee. Aimed at tiny zebrafish bathing in a translucent dish, the camera was recording the movements of immune cells as they migrated through the fish’s tail fins toward the tip of a pipette

A new treatment option for people with acute myeloid leukemia is available, and it works in an unconventional way.

… Wednesday, August 2, 2017 Summary Acute myeloid leukemia is a rare but hard-to-treat blood cancer that primarily affects older adults. The FDA has approved a new medicine for the disease that works in a manner different from standard chemotherapies. The US Food and Drug Administration has approved the

The David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center sets a new benchmark for sustainability and resiliency in a healthcare facility.

… Tuesday, December 10, 2019 The David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center sets a new benchmark for sustainability and resiliency in a healthcare facility. “Safety, coupled with a healthy indoor environment, is the most important assurance we can offer patients, which

A team of investigators from Memorial Sloan Kettering has shown for the first time that tumor growth, metastasis, and chemotherapy resistance are connected to the same molecular changes inside breast cancer cells.

… Friday, July 6, 2012 Summary A team of investigators from Memorial Sloan Kettering has shown for the first time that tumor growth, metastasis, and chemotherapy resistance are connected to the same molecular changes inside breast cancer cells. Doctors who treat patients with breast cancer have known that

Lisa M. DeAngelis, MD and Elizabeth Schille, RN, OCN were recognized for their work in the the field of neuro-oncology.

… Friday, November 6, 2020 Memorial Sloan Kettering (MSK) Physician-in-Chief and Chief Medical Officer  Lisa M. DeAngelis, MD , has been awarded Oligo Nation’s Lifetime Achievement Award for her leadership in the field of neuro-oncology. MSK Registered Nurse Elizabeth Schille, RN, OCN, was also honored

The President and CEO and Chair of the Board at Memorial Sloan Kettering Cancer Center introduce the year's highlights in their introductory letter to the 2023 Annual Report.

… Monday, June 10, 2024 Every day, the people of Memorial Sloan Kettering Cancer Center (MSK) are driven by a singular mission: ending cancer for life. That relentless focus enables us to provide the world’s best, most compassionate care to every person who comes to MSK. It is what propels us to transform

The Organ Preservation in Patients with Rectal Adenocarcinoma (OPRA) trial demonstrated that the watch-and-wait strategy is safe for patients with stage 2 and stage 3 rectal cancers that achieve a clinical complete response (CCR) or near-complete clinical response (NCR) to total neoadjuvant therapy (TNT).

… Tuesday, February 13, 2024 The Organ Preservation in Patients with Rectal Adenocarcinoma (OPRA) trial demonstrated that the watch-and-wait strategy is safe for patients with stage 2 and stage 3 rectal cancers that achieve a clinical complete response (CCR) or near-complete clinical response (NCR) to

MSK researchers have identified a compound that kills glioblastoma cells using a mechanism that’s completely different from earlier treatments.

… Wednesday, March 6, 2019 Summary Using genetically engineered mouse models and high-throughput screening technologies, MSK researchers have found a surprising new approach for targeting glioblastoma. It involves focusing in on cancer stem cells. The type of brain tumor known as glioblastoma (GBM) is